🇺🇸 FDA
Pipeline program

Low Dose GT-02287

GANX-001-V103

Phase 2 small_molecule active

Quick answer

Low Dose GT-02287 for Parkinson Disease is a Phase 2 program (small_molecule) at Gain Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Gain Therapeutics
Indication
Parkinson Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials